| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.3 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.3 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |